REGENXBIO Inc. is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Its NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. Its therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: RGNX
- Previous Close: $17.30
- 50 Day Moving Average: $18.74
- 200 Day Moving Average: $17.00
- 52-Week Range: $7.07 - $24.55
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.41
- P/E Growth: 0.00
- Market Cap: $458.02M
- Outstanding Shares: 26,475,000
- Beta: -0.58
- Net Margins: -661.81%
- Return on Equity: -24.21%
- Return on Assets: -23.16%
Companies Related to REGENXBIO:
- Current Ratio: 6.72%
- Quick Ratio: 6.72%
What is REGENXBIO's stock symbol?
REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."
Where is REGENXBIO's stock going? Where will REGENXBIO's stock price be in 2017?
2 analysts have issued 1-year target prices for REGENXBIO's stock. Their predictions range from $25.00 to $36.00. On average, they expect REGENXBIO's share price to reach $30.50 in the next year.
When will REGENXBIO announce their earnings?
REGENXBIO is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
Who owns REGENXBIO stock?
REGENXBIO's stock is owned by a number of of institutional and retail investors. Top institutional investors include Bain Capital Public Equity Management LLC (9.42%), FMR LLC (8.63%), Perceptive Advisors LLC (4.84%), Franklin Resources Inc. (3.68%), Vivo Capital LLC (1.90%) and State Street Corp (1.16%). Company insiders that own REGENXBIO stock include Fmr Llc and James E Flynn.
Who sold REGENXBIO stock? Who is selling REGENXBIO stock?
REGENXBIO's stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, FIL Ltd and Franklin Resources Inc..
Who bought REGENXBIO stock? Who is buying REGENXBIO stock?
REGENXBIO's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Perceptive Advisors LLC, Nicholas Investment Partners LP, Russell Investments Group Ltd., State Street Corp, Bain Capital Public Equity Management LLC and RTW Investments LP.
How do I buy REGENXBIO stock?
Shares of REGENXBIO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of REGENXBIO stock cost?
One share of REGENXBIO stock can currently be purchased for approximately $17.30.